Literature DB >> 21395657

Extreme bradycardia due to multiple drug-drug interactions in a patient with HIV post-exposure prophylaxis containing lopinavir-ritonavir.

Rachel Puech, Marie-Claude Gagnieu, Caroline Planus, Bruno Charpiat, André Boibieux, Tristan Ferry, Michel Tod.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21395657      PMCID： PMC3080653          DOI： 10.1111/j.1365-2125.2010.03849.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  18 in total

Review 1.  Clinical pharmacology of lacidipine.

Authors:  S T Hall; S M Harding; G L Evans; M Pellegatti; P Rizzini
Journal:  J Cardiovasc Pharmacol       Date:  1991       Impact factor: 3.105

Review 2.  Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.

Authors:  D J Touw
Journal:  Drug Metabol Drug Interact       Date:  1997

3.  Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4.

Authors:  F P Guengerich; W R Brian; M Iwasaki; M A Sari; C Bäärnhielm; P Berntsson
Journal:  J Med Chem       Date:  1991-06       Impact factor: 7.446

4.  Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir.

Authors:  L L von Moltke; D J Greenblatt; J M Grassi; B W Granda; S X Duan; S M Fogelman; J P Daily; J S Harmatz; R I Shader
Journal:  J Clin Pharmacol       Date:  1998-02       Impact factor: 3.126

5.  Influence of hydroxychloroquine on the bioavailability of oral metoprolol.

Authors:  M Somer; J Kallio; U Pesonen; K Pyykkö; R Huupponen; M Scheinin
Journal:  Br J Clin Pharmacol       Date:  2000-06       Impact factor: 4.335

6.  HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.

Authors:  C G Lee; M M Gottesman; C O Cardarelli; M Ramachandra; K T Jeang; S V Ambudkar; I Pastan; S Dey
Journal:  Biochemistry       Date:  1998-03-17       Impact factor: 3.162

7.  Lacidipine and josamycin: two new multidrug resistance modulators.

Authors:  L Crosta; V Candiloro; M Meli; M Tolomeo; L Rausa; L Dusonchet
Journal:  Anticancer Res       Date:  1994 Nov-Dec       Impact factor: 2.480

8.  Inhibition of the enantioselective oxidative metabolism of metoprolol by verapamil in human liver microsomes.

Authors:  M Kim; D D Shen; A C Eddy; W L Nelson; L K Roskos
Journal:  Drug Metab Dispos       Date:  1993 Mar-Apr       Impact factor: 3.922

9.  Induction effects of ritonavir: implications for drug interactions.

Authors:  Michelle M Foisy; Erin M Yakiwchuk; Christine A Hughes
Journal:  Ann Pharmacother       Date:  2008-06-24       Impact factor: 3.154

Review 10.  Clinical pharmacokinetics of ramipril.

Authors:  S Meisel; A Shamiss; T Rosenthal
Journal:  Clin Pharmacokinet       Date:  1994-01       Impact factor: 6.447
View more
  9 in total

1.  Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Authors:  Michel Tod; Christina Nkoud-Mongo; François Gueyffier
Journal:  AAPS J       Date:  2013-09-12       Impact factor: 4.009

2.  Drug-drug interactions--bridging the gulf between the bench and the bedside?

Authors:  Y K Loke
Journal:  Br J Clin Pharmacol       Date:  2011-04       Impact factor: 4.335

Review 3.  Managing drug interactions in HIV-infected adults with comorbid illness.

Authors:  Christine A Hughes; Alice Tseng; Ryan Cooper
Journal:  CMAJ       Date:  2014-09-15       Impact factor: 8.262

4.  Identification of Cytochrome P450-Mediated Drug-Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model.

Authors:  Nicolas Fermier; Laurent Bourguignon; Sylvain Goutelle; Nathalie Bleyzac; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

5.  Population pharmacokinetic modelling to quantify the magnitude of drug-drug interactions between amlodipine and antiretroviral drugs.

Authors:  Perrine Courlet; Monia Guidi; Susana Alves Saldanha; Matthias Cavassini; Marcel Stoeckle; Thierry Buclin; Catia Marzolini; Laurent A Decosterd; Chantal Csajka
Journal:  Eur J Clin Pharmacol       Date:  2021-01-16       Impact factor: 2.953

Review 6.  A Double-Edged Sword-Cardiovascular Concerns of Potential Anti-COVID-19 Drugs.

Authors:  Wen-Liang Yu; Han Siong Toh; Chia-Te Liao; Wei-Ting Chang
Journal:  Cardiovasc Drugs Ther       Date:  2020-06-17       Impact factor: 3.727

Review 7.  Safety and Efficacy of Antiviral Drugs for the Treatment of COVID-19: A Systematic Review.

Authors:  Zhenwang Nie; Tao Sun; Fangcheng Zhao
Journal:  Infect Drug Resist       Date:  2022-08-12       Impact factor: 4.177

Review 8.  Potential drug-drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments.

Authors:  Florian Lemaitre; Caroline Solas; Matthieu Grégoire; Laurence Lagarce; Laure Elens; Elisabeth Polard; Béatrice Saint-Salvi; Agnès Sommet; Michel Tod; Chantal Barin-Le Guellec
Journal:  Fundam Clin Pharmacol       Date:  2020-07-24       Impact factor: 2.747

Review 9.  Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications.

Authors:  Shubham Agarwal; Sanjeev Kumar Agarwal
Journal:  Cardiovasc Drugs Ther       Date:  2020-09-12       Impact factor: 3.727
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.